[en] The efficacy of zolmitriptan (Zomig, 311C90), a 5-hydroxytryptamine (5HT)1B/1D receptor agonist, in the acute oral treatment of migraine was evaluated in an extensive clinical trial program. Four randomized, placebo-controlled studies (total 2480 patients) were performed; data from two of these trials established that a 2.5 mg dose was on the shoulder of the dose-response curve (2-h headache response rate 64%), showing similar efficacy to the 5 mg dose (67%). In this program, the efficacy of zolmitriptan was not influenced by the pretreatment headache duration; the presence of aura preceding the headache, migraine associated with menses or migraine upon awakening; or by concomitant use of oral contraceptives or antidepressants. In addition, zolmitriptan 5 mg proved consistently effective in the treatment of multiple migraine attacks for up to 1 year. Zolmitriptan reduced the incidence of nausea, photophobia and phonophobia, reduced impairment of normal activity and demonstrated positive effects on patients' quality of life. Thus, zolmitriptan is a highly effective acute oral antimigraine therapy, with 2.5 mg providing the optimal balance between efficacy and tolerability.
Disciplines :
Neurology Neurosciences & behavior
Author, co-author :
Schoenen, Jean ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie
Sawyer, J.
Language :
English
Title :
Zolmitriptan (Zomig, 311c90), a Novel Dual Central and Peripheral 5ht1b/1d Agonist: An Overview of Efficacy
Martin GR., Inhibition of the trigemino-vascular system with 5-HT1D agonist drugs: selectively targeting additional sites of action. Eur Neurol 1996; 36 Suppl 2: 13-18
Dechant KL, Clissold SP., Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1992; 43: 776-98
Dixon R, Warrander A., The clinical pharmacokinetics of zolmitriptan. Cephalalgia 1997; 17 Suppl 18: 15-20
Martin G., Pre-clinical pharmacology of zolmitriptan (Zomig× formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia 1997; 17 Suppl 18: 4-14
Goadsby PJ, Hoskin KL., Inhibition of trigeminal neurones by intravenous administration of the serotonin (5HT)1B/1D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic targets in migraine? Pain 1996; 67: 355-9
Schoenen J, Prioetti-Cecchini A, Afra J., Intensity dependence of cortical auditory evoked potentials as an indication of central serotonergic neurotransmission: application to 5HT1D agonists used in acute migraine treatment. Cephalalgia 1997; 17: 388 (Abs 06-A 09)
Edmeads J, Millson DS., Tolerability profile of zolmitriptan (Zomig×; 311C90), a novel dual central and peripheral 5HT1B/1D agonist. Cephalalgia 1997; 17 Suppl 18: 41-52
Rolan P., Potential drug interactions with the novel antimigraine compound zolmitriptan (311C90; Zomig×). Cephalalgia 1997; 17 Suppl 18: 21-7
Schoenen J, Caekebeke P, Louis G, Monseu G, Phillips S, Pierre P., An open study to investigate the absorption and tolerability of oral 311C90 and to obtain a preliminary indication of an efficacy in migraine patients. In: Rose FC, editor. Proceedings of the 10th Migraine Trust Symposium, New Advances in Headache Research 4. London: Smith-Gordon, 1994: 11-12
Pilgrim AJ., Lessons learned from the clinical development of sumatriptan. In: Olesen J, Tfelt-Hansen P, editors. Headache treatment; trial methodology and new drugs. Philadelphia: Lippincott-Raven Publishers, 1997: 119-24
Visser WH, Klein K, Cox RC, Jones D, Ferrari M., 311C90, a new central and peripherally acting 5HT1D receptor agonist in the acute treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology 1996; 46: 552-6
Dahlöf C, Diener HC, Goadsby PJ, Massiou H, Olesen J, Schoenen J, et al. A multicenter, double-blind, placebo-controlled, dose-range finding study to investigate the efficacy and safety of oral doses of 311C90 in the acute treatment of migraine. Headache 1995; 35: 292 (Abs 19)
Rapoport AM, Cady RK, Matthew NT, Ramadan NM, Taylor FR, Saper JR, et al. Optimizing the oral dose of 311C90 in the acute treatment of migraine. Cephalalgia 1995; 15 Suppl 14: 221 (Abs P19). Poster presented a the 7th International Headache Congress, Toronto, 16-20 Sept 1995
Lowy MT, for the US 311C 2.5 mg Study Group. 2.5 mg 311C90 in the acute treatment of migraine: efficacy and safety. Eur J Neurol 1996; 3 Suppl 5: 152 (Abs P409)
Diener HC., Issues in migraine trial design: a case study. Proceedings of the 3rd European Headache Conference, Sardinia, June 5-8 1996: 10-11. Extended abstracts of an official symposium: 311C90: Potential for improving patient care, 6 June 1996
Ferrari MD., 311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D agonists. Neurology 1997; 48 Suppl. 3: S21-4
Zagami AS, for the International 311C90 Long-term Study Group. 311C90: long-term efficacy and tolerability profile for the acute treatment of migraine. Neurology 1997; 48 Suppl 3: S25-8
Solomon GD., Evolution of the measurement of quality of life in migraine. Neurology 1997; 48: S10-15
McKenna S, Patrick D., Development of a migraine specific quality of life measure for multinational clinical trials. Cephalalgia 1995; 15 Suppl 14: 280
Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl 7: 1-96
Rapoport AM, Ward T, Katz DA, Sheftell FD., Zolmitriptam ("Zomig"): rapid onset of migraine relief. Cephalalgia 1997; 17: 422
Brown DL, Sweet RM, Fletcher P., 311C90 is effective in patients who respond poorly to existing antimigraine therapies. Eur J Neurol 1996; 3 Suppl 5: 152 and poster presented at the 2nd Congress of the European Federation of Neurological Sciences, Rome, 30 Oct-3 Nov 1996
Klein KB., Overview of the efficacy of zolmitriptan (311C90): a new acute treatment for migraine. 8th World Congress on Pain, Vancouver Aug 17-22, 1996: 499-500 (Abs)
Bousser MG, D'Allens H, Richard A., Efficacy of subcutaneous sumatriptan in the acute treatment of early morning migraine. J Intern Med 1993; 234: 211-16
Goadsby PJ., Diagnosis and optimum treatment of migraine. CNS Drugs 1994; 1: 245-53
Dahlöf CGH, Dimenas F., Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia 1995; 15: 31-6
Osterhaus JT, Townsend RJ, Gandek B, Ware JK., Measuring the functional status and well-being of patients with migraine headache. Headache 1994; 34: 337-43
